MERTK activation drives osimertinib resistance in EGFR-mutant non-small cell lung cancer.
Yan D, Huelse JM, Kireev D, Tan Z, Chen L, Goyal S, Wang X, Frye SV, Behera M, Schneider F, Ramalingam SS, Owonikoko T, Earp HS, DeRyckere D, Graham DK.
Yan D, et al. Among authors: schneider f.
J Clin Invest. 2022 Aug 1;132(15):e150517. doi: 10.1172/JCI150517.
J Clin Invest. 2022.
PMID: 35708914
Free PMC article.